TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04932252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4368 or placebo tablet
Description: orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4368 or placebo tablet
Description: orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4368 or placebo tablet
Description: orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4368 or placebo tablet
Description: orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4368 or placebo tablet
Description: orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4368 or placebo tablet
Description: orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4368 or placebo tablet
Description: orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4368 or placebo tablet
Description: orally administered
Study: NCT04882345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib is a class 1 new drug,the third-generation small molecule EGFR TKI, which can irreversibly and highly selectively inhibit EGFR sensitive mutations (such as exon 19 deletion and L858R mutation) and T790M resistance mutations.~Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day.
Study: NCT05061043

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy treatment
Description: Control group will receive the routine physical therapy treatment that will include EMS, Infrared and Intermittent stretching of facial muscles for 36 sessions on alternate days, each session comprise 30 minutes for 5 days a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy along with orofacial therapy
Description: Experimental group will receive routine physical therapy along with orofacial therapy (36 sessions on alternate days, each session comprise 45 minutes)
Study: NCT06081322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRRT with 177Lu-EB-FAPI
Description: PRRT with 177Lu-Fibroblast activation protein inhibitor and modified by Evans blue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRRT with 177Lu-EB-FAPI
Description: PRRT with 177Lu-Fibroblast activation protein inhibitor and modified by Evans blue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRRT with 177Lu-EB-FAPI
Description: PRRT with 177Lu-Fibroblast activation protein inhibitor and modified by Evans blue
Study: NCT05402605

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI with AOA
Description: Step 1: All post-ICSI oocytes will be added in the medium drop in AOA dish, these oocytes will be placed in the incubator at 37oC, 6% CO2, and 5% O2 for 20 minutes.~Step 2: After 20 minutes, calcium ionophore stock (Sigma-Aldrich - USA) will be diluted into 10µM drops in AOA dish.~Step 3: After 10 minutes of incubation, all post-ICSI oocytes will be moved to the AOA drop, then this dish will be put back in the incubator for 10 minutes.~Step 4: After 10 minutes, all the oocytes in drop AOA will be moved to another drop for rinsing and then put back in the incubator for 20 minutes.~Step 5: After 20 minutes, the oocytes will be moved into drop AOA and then put back in the incubator for 10 minutes.~Step 6: After 10 minutes, all post-ICSI oocytes will be added in the medium drop, then divided into drops with maximum 3 oocytes per drop for culturing. After that, the culture dish will be put in the K-system G185 incubator at 37oC, 6% CO2, and 5% O2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI without AOA
Description: Conventional ICSI procedure will be performed without the application of AOA.
Study: NCT05554562

Intervention type: OTHER
Intervention: Adductor strength assessment
Description: Adductor strength will be evaluated with HHD (handheld dynamometer) and forceplates (Forceframe), both injured leg and healthy will be assess in order to compare both limbs
Study: NCT06098638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional recommendation and Faradic stimulation program
Description: proper maternal nutrition and fluid intake during breast-feeding per day for 12 weeks and2 sessions per week, each session 20 minutes, for 12 weeks. Frequency of 65 Hz, and width pulse 300 ms, with contraction time 10 sec and relaxation time 10 sec
Study: NCT05186415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
Description: The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations.
Study: NCT05401058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droperidol Injection
Description: About 30min before the end of operation, Droperidol 1.25mg/0.5ml will be administered by intravenous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: About 30min before the end of operation, Normal saline 0.5ml will be administered by intravenous injection.
Study: NCT06098638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional recommendation and Faradic stimulation program
Description: proper maternal nutrition and fluid intake during breast-feeding per day for 12 weeks and2 sessions per week, each session 20 minutes, for 12 weeks. Frequency of 65 Hz, and width pulse 300 ms, with contraction time 10 sec and relaxation time 10 sec

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic and resisted exercise for 12 weeks
Description: Each woman in group (B) participated in a moderate exercise program (aerobic+resistive), 3 days/week, for 12 weeks. The session began with 15 minutes of aerobic exercise on a bicycle ergometer, at 60% of heart rate reserve (HRR), with HRR estimated (220-age-resting heart rate). Then, the participant was performed 15 minutes of resistive exercise (two sets of 8-12 repetitions at 75% of one repetition maximum (1-RM) for basic core exercises in the form of hip lifts, knee extension and flexion, crunches, shoulder flexion and extension, elbow flexion and extension with resistance
Study: NCT05034900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest physiotherapy
Description: Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, postural drainage and coughing techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Description: Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, postural drainage and coughing techniques.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillatory Positive Expiratory Pressure (OPEP) device
Description: Shaker® device will be used.
Study: NCT04856241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Physiotherapists (trained by the research team) train the coaches to deliver Prep-to-Play. The Physiotherapists will also provide face-to-face one-to-one support to each coach at their team's training session (two visits), with all their players.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer support
Description: Coaches shed. Coaches provide each other with support and ideas. Strategies to overcome barriers and motivate players.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational materials
Description: Prep-to-Play program resources are available online for coaches and players to view

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Prep-to-Play program resources are available online for coaches and players to view
Study: NCT05481957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 5-10mg for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valprote
Description: 500\~1000mg for 16 weeks
Study: NCT06458816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Knee Joint Distraction
Description: Non-invasive Distraction device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Knee Joint Distraction
Description: Non-invasive Distraction device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Joint Distraction
Description: no device. manual distraction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Joint Distraction
Description: no device. manual distraction.
Study: NCT05503355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BST-236
Description: In part 1: During the induction (in combination with venetoclax), the BST-236 doses are:~In cohort 1 - 2.3 g/m2/d X6 days In cohort 2 - 2.3 g/m2/d X6 days In cohort 3 - 4.5 g/m2/d X6 days In cohort 4 - 4.5 g/m2/d X6 days In cohort 5 - 4.5 g/m2/d X6 days In part 1: During maintenances (for responding patients) the BST-236 dose- 4.5 g/m2/d X6 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: In part 1: During the induction (in combination with BST-236), the venetoclax doses are:~In cohort 1 - 200 mg QD X 7 days In cohort 2 - 400 mg QD X 7 days In cohort 3 - 200 mg QD X 7 days In cohort 4 - 400 mg QD X 7 days In cohort 5 - 200 mg QD X 14 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used
Study: NCT05220475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fully covered self-expandable metal stent with an anchoring external plastic stent
Description: Extrahepatic malignant biliary obstruction treated with fully covered self-expandable metal stent with an anchoring plastic stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncovered self-expandable metal stent
Description: Extrahepatic malignant biliary obstruction treated with uncovered self-expandable metal stent without an anchoring plastic stent
Study: NCT05274295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetic leg ulcer treatment with adipous SVF
Description: The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
Study: NCT04010578

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MK-7 and vitamin D3
Description: Patients will receive 400 micro-grams of Menaquinone-7 and 80 micro-grams of vitamin D3 per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a placebo each day.
Study: NCT06549244

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximum Inspiratory Pressure monitoring
Description: Lung volumes, pressures and breathlessness scores to be measured in pre and post operative phase of care on the same day

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximum Inspiratory Pressure monitoring
Description: Lung volumes, pressures and breathlessness scores to be measured in pre and post operative phase of care on the same day

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximum Inspiratory Pressure monitoring
Description: Lung volumes, pressures and breathlessness scores to be measured in pre and post operative phase of care on the same day
Study: NCT05329675

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sinphar Lipucan Capsule
Description: oral Sinphar Lipucan Capsule 1# (Arm A), 2# (Arm B), or 3# (Arm C)/day for 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sinphar Lipucan Capsule
Description: oral Sinphar Lipucan Capsule 1# (Arm A), 2# (Arm B), or 3# (Arm C)/day for 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sinphar Lipucan Capsule
Description: oral Sinphar Lipucan Capsule 1# (Arm A), 2# (Arm B), or 3# (Arm C)/day for 90 days
Study: NCT05797272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in-utero HSCT
Description: Pregnant women who are diagnosed to have BHFS affected fetuses and opt for continuation of pregnancy will undergo in-utero HSCT.
Study: NCT04905745

Intervention type: PROCEDURE
Intervention: Korean integrative medicine
Description: Any kind of Korean integrative medicine will be applicable and the treatment will be entirely determined by experienced clinicians. On the premise of the above, the following examples are the treatments applicable to the subject of this observational study.~* Chuna: Chuna therapy is performed on the face and cervical spine to induce decompression of the captured facial nerve. In addition, SJS Non-Resistance Technique-Facial palsy (SJS NRT-F), a technique of Chuna, can be performed to stimulate the intrinsic receptive sensation of the facial muscles to promote the neuromuscular response.~* Acupuncture: acupuncture can be applied on paralyzed muscle and others to improve symptoms and paralysis status.~* Pharmacopuncture: pharmacopuncture can be applied on paralyzed muscle and others to improve symptoms and paralysis status.~* Herbal medicine: It is prescribed according to clinical judgment according to the patient's symptoms and disease status.
Study: NCT06329193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mid-Season Camp Period Loading
Description: The daily gym included warm-up protocol (dynamic stretching of the major muscle groups of the upper and lower extremities and jogging), crunches, sit-ups, reverse sit-ups, prone bridge, side bridge, bench press, mini squat (with body weight and/or ancillary equipment), lunge (with body weight and/or ancillary equipment), leg extension, leg curl, leg press, calf raises (with body weight and/or ancillary equipment), and cool-down protocol (dynamic stretching of the major muscle groups of the upper and lower extremities). The field-based exercises included warm-up protocol (dynamic stretching of the major muscle groups of the upper and lower extremities and jogging), dynamic balance (with different balance trainer such as Both Sides Utilized \[BOSU\], trampoline), tactical training, passing, dribbling, and shooting practice, agility and speed practice, and cool-down protocol (dynamic stretching of the major muscle groups of the upper and lower extremities)
Study: NCT04963725

Intervention type: DRUG
Intervention: Ustekinumab
Description: No intervention or treatment will be administered as part of this study. Data available per routine clinical practice at clinic visits as well as directly from participant using a smartphone/tablet application will be collected.
Study: NCT05435300

Intervention type: OTHER
Intervention: PET Scan
Description: Participants will undergo two PET scans throughout the study.
Study: NCT06518590

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cycle
Description: Kettler upright bike Giro P:

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cycle
Description: Kettler upright bike Giro P:

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cycle
Description: Kettler upright bike Giro P:
Study: NCT04953988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic TKA
Description: Robotic TKA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual operation
Description: Manual operation
Study: NCT05423223

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin Bath Therapy
Description: Device named 'Fizyowax 1300' (Fizyomed, Turkey).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy
Description: Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
Study: NCT05633030

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: using UAS during flexible ureteroscopy and using PCN during flexible ureteroscopy
Description: under general anesthesia and given appropriate antibiotic cover. a clssic flexible ureteroscopy procedure is done and appropriately sized UAS was then inserted over the wire and positioned just distal to the PUJ or below upper ureteric stone under fluoroscopic guidance. We then perform a flexible ureteroscopy using Olympus URF-V2 (8.5 Fr) flexible ureteroscope to inspect the proximal ureter if there is upper ureteric stone, renal pelvis, and calyces for the presence of stones. Irrigation with 0.9% saline solution via a pressure-infusing system. Next, Holmium laser lithotripsy with a holmium:YAG laser \[20 W; Lumenis (UK) Ltd., Elstree, UK\] using a 272 micron laser fiber (Lumenis, Inc.) is carried out and/or stone extraction with a basket device, in the other group we add inserted trans papillary in the lower calyx of the kidney by an expert intervention radiologist

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: using UAS during flexible ureteroscopy and using PCN during flexible ureteroscopy
Description: under general anesthesia and given appropriate antibiotic cover. a clssic flexible ureteroscopy procedure is done and appropriately sized UAS was then inserted over the wire and positioned just distal to the PUJ or below upper ureteric stone under fluoroscopic guidance. We then perform a flexible ureteroscopy using Olympus URF-V2 (8.5 Fr) flexible ureteroscope to inspect the proximal ureter if there is upper ureteric stone, renal pelvis, and calyces for the presence of stones. Irrigation with 0.9% saline solution via a pressure-infusing system. Next, Holmium laser lithotripsy with a holmium:YAG laser \[20 W; Lumenis (UK) Ltd., Elstree, UK\] using a 272 micron laser fiber (Lumenis, Inc.) is carried out and/or stone extraction with a basket device, in the other group we add inserted trans papillary in the lower calyx of the kidney by an expert intervention radiologist
Study: NCT05411627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Therapy
Description: Participants will receive shockwave therapy once per week for three weeks.
Study: NCT04944056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: * Ultrasound therapy 3-4 minutes.~* Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~* Patellar glides 1 set x 5 reps x 3 sets.~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~Home plan:~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Active range of motion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compression mobilization
Description: * Ultrasound therapy 3-4 minutes.~* Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~* Patellar glides 1 set x 5 reps x 3 sets.~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Compression mobilization 1 set x 10 reps x 3sets.~Home plan:~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Active range of motion.
Study: NCT05273502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Citizen Science intervention
Description: Intervention generated by a participatory research process (co-creation) in the elderly population living in rural areas to co-create solutions to improve their lifestyles, quality of life and health.
Study: NCT05209009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAC-2
Description: Intramuscular vaccine against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Intramuscular injection of saline placebo
Study: NCT05133778

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sweet orange and pomegranate extract
Description: From the daily 650mg total supplementation of the investigational product, 250 mg will be of pomegranate extract containing 100mg of punicalagin. The remaining 400 mg will consist of sweet orange peel extract containing 360 mg of hesperidin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin control
Description: Supplementation with 760 mg maltodextrin
Study: NCT05140070

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties
Description: All children in the intervention group will consume on daily basis vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties for six months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vegetable and fruit mousse
Description: All children in the control group will consume on daily basis vegetable and fruit mousse for six months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary and physical activity counselling
Description: All children in the study will obtain 4 dietary and physical activity advice during the course of the study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and physical activity counselling
Description: All children in the study will obtain 4 dietary and physical activity advice during the course of the study
Study: NCT05813340

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vascularized inter-positional periosteal connective tissue flap
Description: It is a vascularized pedicled flap derived from the hard palate that can be used as a barrier to prevent in growth of soft tissue in guided bone regeneration and to increase soft tissue quantity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascularized inter-positional periosteal connective tissue flap
Description: It is a vascularized pedicled flap derived from the hard palate that can be used as a barrier to prevent in growth of soft tissue in guided bone regeneration and to increase soft tissue quantity
Study: NCT04892511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjusted medication
Description: In patients randomized to perfusion optimization, medication will be adjusted to maintain blood pressure according to the degree of recanalization:~* Patients with TICI 2b: systolic blood pressure 140-160 mmHg.~* Patients with TICI 2c-3: systolic blood pressure \<140 mmHg.~Hypotensive drugs will be used when necessary. Intravenous labetalol is the treatment of choice, administered as a bolus or intravenous infusion. Alternative: urapidil (bolus or continuous infusion pump). If both drugs cannot be used or are insufficient, sodium nitroprusside can be used.~Hypertensive drugs for TICI2b patients whose target pressure is 140-160mmHg and are below this range. Initially, a bolus of physiological saline or 100cc Plasmalyte® will be administered. If this treatment is not effective enough (blood pressure measurements persist \<140 mmHg), intravenous phenylephrine will be administered.
Study: NCT04791150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fill in a form
Description: Patient will have to fill in a form at each perfusion of immunotherapy to tell if they presents rheumatologic clinical signs